Exclusive Online Content
AKCEA-APO(a)-LRx Advances as Novartis Exercises Option to License
Akcea Therapeutics, Inc. recently announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD).
U.S. FDA Grants Breakthrough Therapy Designation to Amicus Therapeutics
Amicus Therapeutics recently announced that the US FDA has granted to Amicus a Breakthrough Therapy Designation (BTD) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA).
Sapreme Technologies to Develop an Oligonucleotide Delivery Platform
Sapreme Technologies has been awarded a $7.71 million grant together with a multidisciplinary consortium including 11 other academic and industrial parties.
PPD & HLT to Create Data Science-Driven Clinical Research Solutions
Pharmaceutical Product Development, LLC and Happy Life Tech of China have signed an exclusive agreement to develop a distinctive service offering for the China drug development market delivering data science-driven clinical trials and real-world evidence of drug products’ effectiveness, safety, and value.
Moleculin Announces Out-Licensing Deal to Accelerate Preclinical & Clinical Development
Moleculin Biotech, Inc. recently announced it has entered into a sub-license agreement with WPD Pharmaceuticals (WPD), located in Poland.
Passage Bio Launches With $115.5 Million Financing to Develop AAV-Delivered Therapeutics
Passage Bio recently debuted with a $115.-million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical
DiaMedica Therapeutics Inc. recently announced it has initiated dosing patients with chronic kidney disease (CKD) in a Phase Ib clinical study evaluating DM199.
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License: Triggers Milestone
Codexis, Inc. recently announced that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder.
West Annouces Significant Agreements With Swissfillon & scPharmaceuticals
West recently announced it has commenced discussions with two companies regarding the use of West’s proprietary SmartDose drug delivery platform for complex molecules.
uniQure Announces First Patient Treated in Pivotal Trial
uniQure N.V. recently announced it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
Meridian Launches New Range of Lyo-Ready PCR Mixes
Meridian Bioscience, Inc. recently announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR.
ABITEC Corporation Launches New Versatile Excipient for Oral Dose Applications
ABITEC Corporation, a global manufacturer of specialty lipids, continues to develop products that meet the ever-evolving demands of the pharmaceutical industry.
PCI Pharma Services Announces Bottling Line Expansion to Support Customer Needs
PCI Pharma Services recently announce the expansion of its bottling line capacity at its Commercial Packaging site in Rockford, IL.
AbbVie’s Immunology Pipeline Will Protect it From Biosimilar Erosion
Although AbbVie is feeling the impact of Humira biosimilar launch in Europe, its strong immunology pipeline is likely to protect its hold on the plaque psoriasis (PsO) and rheumatoid arthritis (RA) markets, according to GlobalData, a leading data and analytics company.
First Oral Add-On Treatment to Insulin for Treatment of Certain Patients With Type 1 Diabetes
The EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus.
Hovione Issues $50-Million Bond; Embarks on New Phase of Capital Expansion
Hovione recently announced it issued a bond of $50 million dollars maturing in 2033. The bond was arranged and subscribed by Banco BPI, S.A.
Q BioMed Technology Partner Mannin Research Enters Collaboration With McMaster University
Q BioMed Inc., a biotechnology acceleration company, recently announced its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada.
Pharmapack Report Predicts Diversification of Innovation Leading to a Rise in Licensing & Partnering
Pharmapack Europe (February 6-7, Paris Expo Porte de Versailles, Paris) has released a European Drug Delivery and Packaging report, ahead of the event’s opening, which highlights, major challenges and opportunities for the industry in the year ahead.
TrakCel & Quick Partner to Provide Industry-Leading Digital Supply Chain IT Solution for Cell & Gene Therapies
TrakCel and The Quick Life Science Group recently announced a partnership to offer an integrated IT logistics orchestration platform.
MilliporeSigma & Roche Renew Global Distribution Agreement
MilliporeSigma and Roche recently announced they have agreed to renew their current distribution agreement for the Biochemical Reagents and Kapa Biosystems product portfolios, as well as select qPCR & Nucleic Acid Purification products.
